Trial Profile
A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of pramipexole with the dose range from 0.125 mg to 0.75 mg orally once daily for 6 weeks in patients with primary restless legs syndrome
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2013
Price :
$35
*
At a glance
- Drugs Pramipexole (Primary)
- Indications Restless legs syndrome
- Focus Therapeutic Use
- 16 Jan 2007 Status change
- 11 Dec 2005 New trial record.